ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Renal Tubular Epithelial CRLF1 Interacts With ITGB1 to Accelerate Fibrosis During the Transition From AKI to CKD.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD), ultimately leading to end-stage renal failure. Cytokine receptor-like factor 1 (CRLF1) is a secreted protein with low or undetectable expression in normal physiology, but it is transcriptionally and translationally upregulated under pathological conditions. In this study, we found CRLF1 to be upregulated in the kidneys of patients with ATN and CKD, positively correlated with renal interstitial fibrosis, and negatively correlated with renal function. In vivo functional inhibition studies demonstrated that CRLF1 suppression significantly improved renal function, mitigated pathological damage, and delayed fibrosis progression in mouse models of IRI or UUO. Further in vitro studies revealed that CRLF1 promotes fibrosis and inflammation in renal tubular epithelial cells (TECs). Mechanistically, we employed chromatin immunoprecipitation (ChIP) to validate SMAD3 binding to the CRLF1 promoter and its transcriptional regulation, while elevated CRLF1 interacts with the VWFA domain of integrin β1 (ITGB1). Furthermore, transcriptomic sequencing revealed that CRLF1 activates the PI3K/AKT signaling pathway, promoting tubular epithelial cell fibrosis progression via ITGB1. These findings underscore the critical role of CRLF1 in renal fibrosis progression and suggest its potential as a therapeutic target for inhibiting the progression from AKI to CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.